Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | TROPHY-U-01: cohort 7 of SG, EV and zimberelimab in untreated mUC

Randy Sweis • 23 Oct 2026
ESMO 2026
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma Enfortumab vedotin Sacituzumab govitecan Zimberelimab
TROPHY-U-01

Randy Sweis, MD, University of Chicago, Chicago, IL, discusses interim results from cohort 7 of the Phase Ib TROPHY-U-01 trial (NCT03547973), which evaluated sacituzumab govitecan (SG) combined with enfortumab vedotin (EV) and the PD-1 inhibitor zimberelimab in treatment-naive metastatic urothelial cancer (mUC). Early antitumor activity was promising and the triplet showed manageable toxicity, with no additive toxicity beyond the expected profiles of the individual drugs. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Randy Sweis

Using the urinary microbiome to predict BCG therapy responses in bladder cancer patients.
4:13
Using the urinary microbiome to predict BCG therapy responses in bladder cancer patients.
Randy Sweis • 15 Feb 2019
Immunotherapy resistance mechanisms and predicting NMIBC patient immune responses.
2:05
Immunotherapy resistance mechanisms and predicting NMIBC patient immune responses.
Randy Sweis • 15 Feb 2019
Progress and challenges of immunotherapy for bladder cancer
1:25
Progress and challenges of immunotherapy for bladder cancer
Randy Sweis • 15 Feb 2019

Related Videos

CCTG PR21: patient-reported QoL with docetaxel vs lutetium-PSMA in mCRPC
3:22
CCTG PR21: patient-reported QoL with docetaxel vs lutetium-PSMA in mCRPC
Daniel Khalaf • 23 Oct 2026
Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals